Dr. David Rimm on Immunofluorescence for HER2 Identification

David Rimm MD, PhD
Published: Monday, Jan 26, 2015

David Rimm MD, PhD, professor of pathology and medicine, director of pathology tissue services, Yale University School of Medicine, explains the benefits of quantitative immunofluorescence for the measurement of HER2 proteins. 

Most immunohistochemistry (IHC) assays, which are traditionally used for the measurement of HER2 proteins, have a 10% to 20% false negative and false positive rate. Quantitative immunofluorescence is more accurate, sensitive, has twice as much dynamic range, and it is more reproducible, says Rimm.  The technology makes it easier to match patients with their most effective therapies. 

This practice has not yet caught on with many pathologists yet, but Rimm believes the field will move into that direction once pathologists begin to see its value and it becomes standard practice. 

David Rimm MD, PhD, professor of pathology and medicine, director of pathology tissue services, Yale University School of Medicine, explains the benefits of quantitative immunofluorescence for the measurement of HER2 proteins. 

Most immunohistochemistry (IHC) assays, which are traditionally used for the measurement of HER2 proteins, have a 10% to 20% false negative and false positive rate. Quantitative immunofluorescence is more accurate, sensitive, has twice as much dynamic range, and it is more reproducible, says Rimm.  The technology makes it easier to match patients with their most effective therapies. 

This practice has not yet caught on with many pathologists yet, but Rimm believes the field will move into that direction once pathologists begin to see its value and it becomes standard practice. 


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x